ArticleTherapeutic advances in chronic disease2022
Increased IL-31 expression in serum and tissue protein in prurigo nodularis.
Article in Therapeutic advances in chronic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Differences in Itch Quality Between Interleukin-31 and Thymus and Activation-Regulated Chemokine of Japanese Atopic Dermatitis.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- From neuroimmune circuits to targeted therapy of chronic pruritus.Pharmacological reviews · 2026Review
- Prurigo Nodularis and the Pain Cascade: Understanding the Pathogenesis and Approach to Management.The Journal of clinical and aesthetic dermatology · 2026Review
- Th2 mRNA gene expression analysis separates Prurigo nodularis into two immune signature groups.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Observational
- New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Anti-atopic dermatitis effect of fraxinellone via inhibiting IL-31 in vivo and in vitro.Heliyon · 2024Article
- Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo.International journal of molecular sciences · 2024Article
- Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation.Scientific reports · 2024Article
- Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.American journal of clinical dermatology · 2024Review
- In chronic spontaneous urticaria, IgE and C-reactive protein are linked to distinct microRNAs and interleukin-31.Clinical and translational allergy · 2023Article
- Molecular mechanisms of pruritus in prurigo nodularis.Frontiers in immunology · 2023Review
- Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prurigo nodularis (PN) is a chronic pruritic skin disease which can greatly impact patients' quality of life. Moreover, the pathogenesis remains unclear, making it a difficult-to-treat condition. Aims: To investigate the expression of interleukin-31 (IL-31) in serum and skin biopsy specimens of PN patients and healthy subjects and identify its possible correlation to disease severity and itch intensity. Methods: Patients with PN and healthy volunteers were recruited for the study. Expression levels of IL-31 were measured by enzyme-linked immunosorbent assay and immunohistochemistry. Baseline characteristics, disease activity, itch intensity, and related laboratory results were collected. Results: Forty-three PN patients and 31 healthy subjects participated in our study. The PN patients had significantly higher mean serum IL-31 levels than the healthy subjects (52.9 ± 18.2 Conclusion: Increased IL-31 expression in serum and PN lesions suggests that IL-31 has a potential role in the pathogenesis of PN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.